Results 41 to 50 of about 4,938,261 (300)

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

International Journal of Molecular Sciences, 2020
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is the most aggressive subtype from a clinical standpoint, posing a great challenge to clinicians. Whilst the biological consequences of the three MPN driver
E. Rumi, C. Trotti, D. Vanni, I. Casetti, D. Pietra, Emanuela Sant'Antonio   +5 more
semanticscholar   +1 more source

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

Frontiers in Oncology, 2022
In primary myelofibrosis, extra-domain A fibronectin (EDA-FN), the result of alternative splicing of FN gene, sustains megakaryocyte proliferation and confers a pro-inflammatory phenotype to bone marrow cell niches. In this work we assessed the levels of
Alessandro Malara, Cristian Gruppi, Margherita Massa, Maria Enrica Tira, Vittorio Rosti, Alessandra Balduini, Giovanni Barosi   +6 more
doaj   +1 more source

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice

Leukemia, 2020
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by clonal myeloproliferation, progressive bone marrow (BM) fibrosis, splenomegaly, and anemia.
Yoshinori Ozono, K. Shide, T. Kameda, Ayako Kamiunten, Yuki Tahira, M. Sekine, Keiichi Akizuki, Kenichi Nakamura, Hisayoshi Iwakiri, Mitsue Sueta, T. Hidaka, Y. Kubuki, Shojiro Yamamoto, S. Hasuike, A. Sawaguchi, K. Nagata, K. Shimoda   +16 more
semanticscholar   +1 more source

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018 [PDF]

BMC Cancer, 2019
Research into Philadelphia-negative chronic myeloproliferative neoplasms is heterogeneous. In addition, no systematization of studies of polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF) have been carried out.
Mónica Mejía-Ochoa, Paola Andrea Acevedo Toro, Jaiberth Antonio Cardona‐Arias   +2 more
openalex   +2 more sources

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

Revista Brasileira de Hematologia e Hemoterapia, 2014
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce, Maria de Lourdes Lopes Ferrari Chauffaille, Silvia Saiuli Miki Ihara, Maria Regina Regis Silva   +3 more
doaj   +1 more source

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

European Journal of Haematology, 2020
COVID‐19 carries a high risk of severe disease course, particularly in patients with comorbidities. Therapy of severe COVID‐19 infection has relied on supportive intensive care measures. More specific approaches including drugs that limit the detrimental
S. Koschmieder, E. Jost, C. Cornelissen, Tobias Müller, M. Schulze-Hagen, J. Bickenbach, G. Marx, M. Kleines, N. Marx, T. Brümmendorf, M. Dreher   +10 more
semanticscholar   +1 more source

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]

, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M., Casale, B., Cerchione, C., Crisa, E., Giordano, C., Grimaldi, F., Iovine, M., Luciano, L., Martinelli, V., Nappi, D., Pane, F., Pezzullo, L., Picardi, M., Pugliese, N., Villa, M. R.   +14 more
core   +1 more source

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Leukemia, 2018
International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and ...
A. Tefferi, P. Guglielmelli, M. Nicolosi, F. Mannelli, M. Mudireddy, N. Bartalucci, C. Finke, T. Lasho, C. Hanson, R. Ketterling, K. Begna, N. Gangat, A. Pardanani, A. Vannucchi   +13 more
semanticscholar   +1 more source

Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy

Archives of Stem Cell and Therapy, 2020
Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) that portends a poor prognosis and has limited options for treatment. PMF is often driven by clonal mutations in one of three genes that regulate the JAK-STAT signaling pathway ...
Andrew J. Piasecki, O. Leiva, K. Ravid
semanticscholar   +1 more source